SCHEMBL349193

SCHEMBL349193

COc1cc(CC(=O)O)c(C(=O)O)c(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.61
▸ KDM4E B2RXH2 2/20 0.60
▸ ABL1 P00519 1/20 0.60
▸ POLB P06746 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ RECQL P46063 1/20 0.60
▸ RIN1 Q13671 1/20 0.60
▸ CTDSP1 Q9GZU7 1/20 0.60
▸ CYP3A4 P08684 3/20 0.47
▸ USP2 O75604 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ THRB P10828 1/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ FNTA P49354 1/20 0.42
▸ FNTB P49356 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347816 0.87 KDM4E (0.47) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL18280338 0.83 CYP3A4 (0.47) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL18280466 0.83 CYP3A4 (0.47) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL466144 0.82 CYP3A4 (0.60) HSD17B10KDM4EPOLBMAPTRECQL
SCHEMBL4395434 0.80 HSD17B10 (0.61) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL3326056 0.80 HSD17B10 (0.61) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL27942158 0.80 HSD17B10 (0.61) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL3971502 0.80 CYP3A4 (0.44) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL6501994 0.79 KDM4E (0.49) HSD17B10KDM4EABL1POLBMAPT
SCHEMBL21710540 0.78 PTGES (0.64) CYP3A4THRBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210361656-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2021-11-25 — — US disclosed
US-20200352946-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. 2020-11-12 — — US disclosed
US-20180104245-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2018-04-19 — — US disclosed
US-20160106750-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2016-04-21 — — US disclosed
US-9199990-B2 Compounds for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2015-12-01 — — US disclosed
US-20150072955-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (US) 2015-03-12 — — US disclosed
EP-2314295-B1 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices RESVERLOGIX INC (CA) 2015-01-28 — — EP disclosed
US-8889698-B2 Compounds for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2014-11-18 — — US disclosed
US-20130281397-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US disclosed
WO-2013156869-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — WO disclosed
EP-1909788-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2008-04-16 — — EP disclosed
WO-2007016525-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2007-02-08 — — WO disclosed
US-20050043411-A1 Process for preparing homophthalate derivatives TJGEL, LLC 2005-02-24 — — US disclosed
US-6797838-B2 Process for preparing homophthalate derivatives ILEX PRODUCTS, INC. 2004-09-28 — — US disclosed
EP-1404662-A2 PROCESS FOR PREPARING ISOCOUMARINS Ilex Products, Inc. (US) 2004-04-07 — — EP disclosed
US-20040024240-A1 Process for preparing homophthalate derivatives GENZYME CORPORATION 2004-02-05 — — US disclosed
US-6664401-B2 Reacting a isochroman-1,3-dione with a carbonyl compound whose carbonyl group is substituted with an acyl activating group, in the presence of a base and a solvent; use making anticancer agents for example ILEX PRODUCTS, INC. 2003-12-16 — — US disclosed
US-20030105340-A1 Process for preparing isocoumarins GENZYME CORPORATION 2003-06-05 — — US disclosed
EP-1300403-A1 Process for the manufacture of hypoxyxylerone derivatives Aventis Pharma S.A. (FR) 2003-04-09 — — EP disclosed
WO-2003004486-A2 PROCESS FOR PREPARING ISOCOUMARINS ILEX PRODUCTS, INC. (US) 2003-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180104245-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 HSD17B10 254/4885KDM4E 4404/4885ABL1 4316/4885
US-20130281397-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION BRD4, BMI1, BRPF3 HSD17B10 3720/4885KDM4E 202/4885ABL1 1317/4885
US-20210361656-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 HSD17B10 254/4885KDM4E 4404/4885ABL1 4316/4885
US-20030105340-A1 Process for preparing isocoumarins DHPS, IDH2, IDH1 HSD17B10 97/4885KDM4E 1498/4885ABL1 202/4885
US-20200352946-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 HSD17B10 254/4885KDM4E 4404/4885ABL1 4316/4885
US-20160106750-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 HSD17B10 254/4885KDM4E 4404/4885ABL1 4316/4885
US-20150072955-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 HSD17B10 254/4885KDM4E 4404/4885ABL1 4316/4885
US-20050043411-A1 Process for preparing homophthalate derivatives HPD, HAAO, PAH HSD17B10 200/4885KDM4E 1794/4885ABL1 1134/4885
US-20040024240-A1 Process for preparing homophthalate derivatives HPD, HAAO, PAH HSD17B10 200/4885KDM4E 1794/4885ABL1 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback